Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Positive lessons of negative trials

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.10.16
Views: 3005
Rating:

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

Dr Gyawali meets with ecancertv at ESMO 2016 to discuss the value of negative trials, considering the slow progression in treating ovarian cancer.

He considers statistically positive studies that have limited benefit for patient survivals, trials finding improved progression-free survival but which fail for not meeting other primary endpoints, and the central importance of patient benefit in trial design.

Read Dr Gyawali’s article "Negative trials in ovarian cancer: is there such a thing as too much optimism?" here.

Dr Gyawali spoke further with ecancer about the balancing of risk and overall survival for patients treated with sorafenib, and contributes a regular blog with his views on recent research.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation